Myomectomy Market in North America to Dominate Due to High Fibroid Prevalence

As women’s reproductive healthcare gains greater global attention, uterine fibroids—a common but often under-discussed condition—are emerging as a significant medical concern. Affecting an estimated 70–80% of women by the age of 50, fibroids can lead to serious symptoms including excessive menstrual bleeding, pelvic pain, and compromised fertility. Myomectomy, a surgical procedure aimed at removing fibroids while preserving the uterus, is increasingly becoming the preferred alternative to hysterectomy. As medical professionals and patients alike place growing emphasis on fertility preservation and minimally invasive treatment options, the myomectomy market is poised for strong growth. According to market data, the global myomectomy market stood at US$ 642.1 Mn in 2024, and is projected to reach US$ 1,430.7 Mn by 2035, advancing at a CAGR of 7.5% from 2025 to 2035.

Access key findings and insights from our Report in this sample

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86660

The Clinical and Economic Need for Myomectomy

The rise in demand for myomectomy stems from a growing clinical need to address uterine fibroids in a way that maintains reproductive potential. With shifting societal norms, more women are delaying childbirth until their 30s or 40s—coincidentally, the age range most affected by fibroids. For these women, preserving the uterus is often of paramount importance. As a uterus-sparing surgical option, myomectomy is increasingly considered superior to hysterectomy, especially among patients prioritizing fertility or concerned about psychological and social implications tied to uterus removal.

In addition to clinical benefits, the rising popularity of myomectomy is also economically driven. With healthcare systems around the world emphasizing patient-centered care, cost-effectiveness, and recovery time, minimally invasive myomectomy procedures, such as laparoscopic and robotic approaches, align well with these objectives. However, accessibility remains a barrier in low- and middle-income nations due to the high costs and limited availability of specialized surgical expertise.

Segmentation by Procedure Type: Open Myomectomy Still Leading

The myomectomy market can be segmented into four primary procedure types: open myomectomy, laparoscopic myomectomy, hysteroscopic myomectomy, and robotic laparoscopic myomectomy. Among these, open myomectomy continues to dominate, especially for large or multiple fibroids that deeply penetrate uterine muscle. This method offers better visibility and maneuverability for surgeons handling complex cases and remains widely practiced in both developed and developing countries.

Despite the longer recovery period and higher complication rates associated with open surgery, it is often the only viable option in certain cases. For instance, in countries with limited access to robotic or laparoscopic tools, open myomectomy becomes the default. Moreover, a 2023 study published in Obstetrics & Gynecology International indicated that approximately 65% of patients with fibroids larger than 8 cm underwent open procedures due to the surgery’s complexity and limited alternative options.

In contrast, laparoscopic and robotic myomectomy are gaining popularity in urban centers of high-income countries due to their reduced hospitalization times, lower pain levels, and faster return to normal activities. However, adoption is currently limited by their higher costs, need for extensive surgical training, and availability of advanced surgical systems.

Product Landscape: Technology as a Catalyst

The product segment supporting myomectomy procedures includes a variety of specialized surgical instruments such as laparoscopic power morcellators, harmonic scalpels, laparoscopic vessel sealers, hysteroscopic resectoscopes, myomectomy forceps, and myoma screw instruments. Also included are other essential tools like retractors, myoma knives, and speculums.

Technological innovations in this area are improving precision, reducing surgical time, and enhancing safety. Noteworthy is the Sonata System by Gynesonics, which combines real-time intrauterine ultrasound guidance with radiofrequency ablation. The September 2024 release of the SMART OS 2.4 software for the Sonata System marks a significant leap forward in non-invasive fibroid treatment. It enables fibroid ablation without incisions, using graphical overlays and live imaging to improve targeting accuracy.

Similarly, Intuitive Surgical’s FDA-cleared da Vinci 5 robotic system, announced in March 2024, represents a milestone in robotic-assisted myomectomy. This next-generation system enhances tactile feedback, surgical dexterity, and precision—capabilities that are particularly beneficial in myomectomy where uterine reconstruction is crucial for future fertility.

Want to know more? Get in touch now

https://www.transparencymarketresearch.com/contact-us.html

Geographic Analysis: North America Takes the Lead

North America commands the largest share in the global myomectomy market, with the U.S. at the forefront due to high fibroid prevalence—particularly among African-American women, who are nearly twice as likely to develop fibroids compared to white women. The region also benefits from high awareness, advanced healthcare infrastructure, and widespread availability of skilled gynecologic surgeons. Furthermore, strong reimbursement frameworks from providers like CMS (Centers for Medicare & Medicaid Services) help promote the adoption of both traditional and minimally invasive procedures.

Research institutions such as the Mayo Clinic and the Cleveland Clinic play a pivotal role in pioneering treatment innovations and setting clinical guidelines for fibroid management. Public health campaigns, women’s health advocacy, and increased screening further contribute to early diagnosis and timely surgical intervention.

Outside North America, Europe also holds a notable share of the market, with countries like Germany, France, and the UK showing strong adoption of minimally invasive technologies. Meanwhile, Asia Pacific is an emerging hotspot due to rising awareness, growing health expenditure, and improving surgical infrastructure, although affordability remains a limiting factor.

End-User Analysis: From Hospitals to Ambulatory Surgical Centers

While hospitals and specialty clinics remain the primary providers of myomectomy procedures, the shift toward ambulatory surgical centers (ASCs) is becoming increasingly apparent. These outpatient settings offer lower costs, reduced infection risks, and quicker discharge times, making them attractive to both patients and payers. With advancements in laparoscopic and robotic systems that allow for same-day discharge, ASCs are expected to see growing volumes of myomectomy procedures in the coming years.

Competitive Landscape: Innovation and Expansion Strategies

Leading players in the myomectomy market are pursuing a mix of organic and inorganic strategies to retain competitive advantage. Companies such as Medtronic, Stryker Corporation, Hologic, Inc., Intuitive Surgical, Olympus Corporation, and Gynesonics are heavily investing in R&D, with a focus on improving imaging precision, reducing invasiveness, and expanding their reach in emerging markets.

Collaborations with academic institutions, strategic acquisitions, and regional expansions are also common tactics. These partnerships enable companies to harness the latest clinical findings, streamline regulatory approvals, and introduce customized solutions tailored to regional healthcare demands.

Explore our report to uncover in-depth insights
https://www.transparencymarketresearch.com/myomectomy-market.html

Conclusion: The Future of Fibroid Treatment

As the landscape of women’s health evolves, myomectomy is poised to play an increasingly prominent role in addressing fibroids while supporting reproductive goals. The convergence of clinical need, patient preference, and technological innovation is fostering a market environment ripe for growth. Despite challenges such as cost and access disparity in lower-income regions, the global momentum toward uterus-preserving, minimally invasive treatments is undeniable.

The coming decade will see continued efforts to enhance procedural safety, optimize outcomes, and ensure equitable access—transforming myomectomy from a specialized surgery into a mainstream reproductive health solution for millions of women worldwide.